嵌合抗原受体
西妥昔单抗
Jurkat细胞
癌症研究
CD16
抗原
抗体
免疫疗法
NFAT公司
T细胞
提吉特
免疫检查点
CD19
化学
免疫系统
单克隆抗体
免疫学
医学
生物
CD3型
移植
CD8型
内科学
钙调神经磷酸酶
作者
Yijian Li,Qianqian Gao,Huan Liu,Shufen Lin,Huanyi Chen,Renpeng Ding,Ying Gu,Cheng‐Chi Chao,Xuan Dong
标识
DOI:10.1080/07357907.2021.1894570
摘要
The switchable chimeric antigen receptors (CARs) have shown many advantages in CAR T-cell therapy. However, human primary T-cells are required to evaluate antigen-specific adaptors by IFN-γ assay or FACS analysis, which limits the throughput of adaptor screening. A sensitive and robust CD16-CAR Jurkat NFAT-eGFP reporter system has been developed to assess the therapeutic efficacy of antibody-targeted CAR-T-cell by effectively evaluating the T-cell activation by various tumor cells and the impact of immune checkpoint inhibitor antibodies. This reporter system facilitates the screening of targeted antibodies in a high throughput manner for the development of improved T-cell immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI